Pressure is on FDA, policymakers and academic centers in the U.S. to respond to challenges from China, Australia, and beyond to run first in human trials faster and more efficiently. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss how stakeholders in the U.S. are responding to the challenge.
The analysts also discuss the next frontiers of federated learning in drug discovery and the latest crop of biotech IPOs on NASDAQ, which raised over $1.2B in strong IPO run last week.
View full story: https://www.biocentury.com/article/660433
#ClinicalTrials #BiopharmaPolicy #DrugDevelopment #BiotechIPO #FederatedLearning
00:00- Introduction
01:15 - Academic Centers
10:42 - Policy Picture
15:48 - Grand Rounds Europe Highlights
18:01 - Federated Learning
28:15 - NASDAQ IPOs
To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected].
Fler avsnitt av BioCentury This Week
Visa alla avsnitt av BioCentury This WeekBioCentury This Week med BioCentury finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.
